The results of the present study suggest that Niv and Atz displayed superior efficacy and safety profiles than did Ram+Doc for relapsed or refractory advanced NSCLC in patients lacking the PD-L1 constraint. The gene discussed is CD274; the disease is non-small cell lung carcinoma.